Daptomycin Hospira 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/03/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, Annex 
II and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
N/0021 
Minor change in labelling or package leaflet not 
01/03/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0019 
B.II.g.5.b - Implementation of changes foreseen in 
22/12/2021 
n/a 
an approved change management protocol - 
Requires further supporting data 
R/0018 
Renewal of the marketing authorisation. 
16/09/2021 
12/11/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Daptomycin Hospira in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0017/G 
This was an application for a group of variations. 
15/03/2021 
n/a 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0016 
A.7 - Administrative change - Deletion of 
05/02/2021 
12/11/2021 
Annex II and 
manufacturing sites 
PL 
II/0014/G 
This was an application for a group of variations. 
10/12/2020 
12/11/2021 
SmPC and PL 
A.7 - Administrative change - Deletion of 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
B.I.a.1.b - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 3/7 
 
 
 
 
 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/11/2020 
12/11/2021 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0013 
C.I.11.z - Introduction of, or change(s) to, the 
18/09/2020 
12/11/2021 
SmPC, Annex 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II and Labelling 
N/0012 
Minor change in labelling or package leaflet not 
02/12/2019 
12/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0011/G 
This was an application for a group of variations. 
21/08/2019 
01/10/2019 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0010 
Minor change in labelling or package leaflet not 
09/04/2019 
01/10/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
20/12/2018 
01/10/2019 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0008 
Transfer of Marketing Authorisation 
25/09/2018 
14/11/2018 
SmPC, 
Labelling and 
PL 
II/0006/G 
This was an application for a group of variations. 
13/09/2018 
14/11/2018 
SmPC, 
B.II.a.3.b.2 - Changes in the composition 
(excipients) of the finished product - Other excipients 
Labelling and 
PL 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Qualitative or quantitative changes in one or more 
excipients that may have a significant impact on the 
safety, quality or efficacy of the product 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/04/2018 
14/11/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0005 
C.I.6.b - Change(s) to therapeutic indication(s) - 
10/01/2018 
08/02/2018 
SmPC, 
Deletion of a therapeutic indication 
Labelling and 
PL 
II/0003 
B.I.b.1.f - Change in the specification parameters 
07/12/2017 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Change outside the 
approved specifications limits range for the AS 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001/G 
This was an application for a group of variations. 
23/11/2017 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
N/0004 
Minor change in labelling or package leaflet not 
20/11/2017 
08/02/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0002 
B.I.b.1.z - Change in the specification parameters 
23/08/2017 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
